1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

FDA plans to review Vivus's anti-obesity drug Qnexa in July

 
• By Nancy Faigen

Vivus said an FDA advisory committee is tentatively scheduled to review the company's NDA for its anti-obesity drug Qnexa (phentermine plus topiramate) on 15 July. The panel would be the endocrinologic and metabolic drugs advisory committee.

Vivus said an FDA advisory committee is tentatively scheduled to review the company's NDA for its anti-obesity drug Qnexa (phentermine plus topiramate) on 15 July. The panel would be the endocrinologic and metabolic drugs advisory committee.

Vivus filed its NDA for the product on 28 December, backed by three positive trials (scripnews.com, 30 December 2009).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category